ArticleJournal of ophthalmic inflammation and infection2026
Evaluation of corneal intrastromal voriconazole injection as an adjuvant approach in recalcitrant fungal keratitis.
Article in Journal of ophthalmic inflammation and infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFungal keratitis is a sight-threatening condition that accounts for approximately 30-40% of keratitis cases in developing countries. Its management remains challenging despite the availability of various antifungal agents, highlighting the potential role of targeted drug delivery in recalcitrant cases. PURPOSE: To evaluate the efficacy of corneal intrastromal voriconazole (ISV) injection in the management of fungal keratitis unresponsive to conventional antifungal therapy.
methodsThis prospective interventional case series included 21 eyes of 21 patients with smear-positive fungal keratitis that failed to respond to at least two weeks of topical antifungal therapy. All patients underwent detailed ophthalmological examination and ulcer assessment using anterior segment optical coherence tomography (AS-OCT). Intrastromal voriconazole (50 µg/0.1 mL) was administered circumferentially around the ulcer. Treatment response was evaluated through serial follow-up, including assessment of ulcer size, infiltrate extent, hypopyon level, presence of satellite lesions, and best-corrected visual acuity (BCVA).
resultsThe mean age of the patients was 57.19 ± 6.74 years, with a predominance of males (76.2%). Most patients were from rural areas (76.2%) and had a history of vegetative trauma (71.4%). The mean ulcer size was 4.64 ± 0.95 mm, and the mean infiltrate size was 6.43 ± 1.29 mm. Hypopyon was present in 57.1% of cases, and the mean ulcer depth measured by AS-OCT was 257.14 ± 68.12 μm. Aspergillus was the most isolated organism (52.4%). BCVA improved significantly from 2.71 ± 0.46 LogMAR at baseline to 1.34 ± 0.68 at 3 months (P < 0.001). Complete resolution was achieved in 19 patients (90.5%). Fourteen patients (66.7%) responded to a single injection, while five (23.8%) and two (9.5%) required two and three injections, respectively. Most cases (84.2%) resolved within 2-4 weeks. Two patients (9.5%) showed disease progression and required therapeutic penetrating keratoplasty and were excluded from the final analysis.
conclusionIntrastromal voriconazole injection appears to be an effective adjunctive treatment for recalcitrant fungal keratitis, improving clinical outcomes and potentially reducing the need for therapeutic or tectonic keratoplasty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.